医药行业周报：X4创新小分子疗法Mavorixafor上市申请获EMA受理

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding the CSI 300 Index by more than 5% in the next six months [11]. Core Views - The pharmaceutical sector experienced a slight decline of -0.02% on January 27, 2025, outperforming the CSI 300 Index by 0.39 percentage points, ranking 16th among 31 sub-industries [6]. - Notable performers within the pharmaceutical sub-industries included pharmaceutical distribution (+0.95%), offline pharmacies (+0.89%), and blood products (+0.40%), while vaccines (-0.70%), medical research outsourcing (-0.70%), and hospitals (-0.52%) lagged behind [6]. - X4 Pharmaceuticals announced that its drug Mavorixafor for treating WHIM syndrome has received acceptance for marketing authorization application (MAA) by the European Medicines Agency (EMA) [7]. - Lu Kang Pharmaceutical (600789) forecasts a net profit of 350-415 million RMB for 2024, representing a year-on-year growth of 42%-69% [7]. - Kailai Ying (002821) anticipates a net profit of 850-1,050 million RMB for 2024, a decline of 54%-63% year-on-year, although revenue from small molecule CDMO is expected to grow by 11% [7]. Summary by Sections Market Performance - As of January 27, 2025, the pharmaceutical sector's performance was -0.02%, with a 0.39% outperformance against the CSI 300 Index, ranking 16th among 31 sub-industries [6]. Industry News - X4 Pharmaceuticals' Mavorixafor, a CXCR4 receptor small molecule antagonist, is under evaluation for treating rare primary immunodeficiency diseases [7]. Company News - Lu Kang Pharmaceutical expects a significant increase in net profit for 2024, while Kailai Ying anticipates a substantial decline in net profit but expects growth in specific business segments [7][8].